BDTX Historical PE Ratio Notes

— Black Diamond Therapeutics (ticker symbol: BDTX) is a precision oncology biotechnology company focused on discovering & developing targeted therapies for patients with genetically defined cancers, particularly those driven by oncogenic mutations in genes such as EGFR & HER2. Since its founding, BDTX has not yet commercialized any products—its revenue primarily comes from research collaborations, partnerships, or grants, not from product sales. This developmental-stage status means that the company typically reports little to no revenue & consistent net losses, rather than earnings. As a result, historical price-to-earnings (PE) ratio data for BDTX is either not meaningful (due to negative earnings) or unavailable (as the denominator in the PE calculation is negative or zero). When reviewing historical PE ratio charts & tables for BDTX, you will likely see either no values or extreme, not-comparable numbers during periods of negative earnings. This reflects the stock market's general focus on BDTX's growth prospects, scientific progress, & clinical trial milestones, rather than traditional profitability metrics like earnings per share (EPS) used for mature companies. Investors often look at other valuation measures or qualitative factors rather than relying on PE ratio analysis for clinical-stage biotechs such as BDTX.

On this page we presented the BDTX Historical PE Ratio information for Black Diamond Therapeutic' stock. The average BDTX historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 0.4. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average BDTX historical PE based on this TTM earnings result method is 14.0. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this BDTX historical PE result, against the recent PE: when this page was posted on 8/21/2026, the most recent closing price for BDTX had been 2.21, and the most recent quarterly earnings result, annualized, was 3.92. Meanwhile, the most recent TTM earnings summed to 0.37. From these numbers, we calculate the recent BDTX PE on 8/21/2026 based on annualized quarterly EPS was 0.6. Based on BDTX's history, that recent PE is elevated relative to the historical average, with the recent PE 50.0% higher than the historical average PE across our data set for Black Diamond Therapeutic. Looking at the recent BDTX PE on 8/21/2026 based on TTM EPS, we calculate the ratio at 6.0. Based on BDTX's history, that recent PE is low relative to the historical average, with the recent PE 57.1% lower than the average PE across our Black Diamond Therapeutic data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on BDTX or any other given stock, valuation analysis for BDTX can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Black Diamond Therapeutic PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for BDTX. Thanks for visiting, and the next time you need to research BDTX Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.